Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Germander refers primarily to *Teucrium chamaedrys*, a perennial herb in the mint family (Lamiaceae) native to central and southern Europe, North Africa, and the Middle East. Its aerial parts have been used historically in traditional medicine for conditions such as gout, diabetes, obesity, digestive complaints, fever, and inflammatory conditions. Mechanistically, germander contains numerous bioactive compounds, most notably furan-containing neoclerodane diterpenoids (e.g., teucrin A, teuchmaedryn A), which are implicated in its marked hepatotoxicity, as they are metabolized by cytochrome P450 enzymes into reactive metabolites causing liver cell injury via glutathione depletion and protein binding. Despite its historical uses, germander is considered likely unsafe and is banned for oral use in several countries due to its association with severe and sometimes fatal liver injury. Its therapeutic benefit in humans is unproven; current use is extremely limited and generally discouraged[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on germander.